PALO ALTO, CA., June 30, 2025 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), the biopharmaceutical company dedicated to developing transformative genetic medicines, today announced that it has raised $300 million in immediate, non-dilutive capital. This financing stems from a royalty monetization agreement, where BridgeBio sold a portion of its future European royalties for its ATTR-CM therapy, acoramidis (marketed as BEYONTTRA in Europe and Attruby in the U.S.) to HealthCare Royalty (HCRx) and funds managed by Blue Owl Capital.

Under the terms of the agreement, BridgeBio monetizes 60% of its European royalties on the first $500 million of annual BEYONTTRA net sales. Importantly, total payments to HCRx and Blue Owl are capped at 1.45x the initial investment, after which no further payments are due.

Science Significance

BEYONTTRA (acoramidis) is a near-complete transthyretin (TTR) stabilizer, indicated for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). In the pivotal ATTRibute-CM Phase 3 trial, acoramidis demonstrated:

  • 42% reduction in composite all-cause mortality (ACM) and recurrent cardiovascular hospitalizations (CVH) versus placebo at 30 months.
  • 50% reduction in cumulative CVH events at 30 months.
  • Rapid separation from placebo in time-to-first event within just 3 months.

These results highlight acoramidis as one of the most effective treatments to date for both wild-type (ATTRwt-CM) and variant (ATTRv-CM) disease, marking a major advance in amyloidosis science

Regulatory Significance

Advertisement

cGxPJobs Banner

Acoramidis is approved as Attruby™ in the U.S. by the FDA, and as BEYONTTRA® by the European Commission, Japan’s PMDA, and the UK’s MHRA. These global approvals underscore regulatory recognition of its strong clinical efficacy and safety profile. The current financing aligns with a broader regulatory strategy to accelerate access and expand patient reach across regions.

Business Significance

The transaction provides non-dilutive capital, monetizing 60% of European royalties on the first $500 million of annual BEYONTTRA® net sales, capped at 1.45x. This ensures BridgeBio retains long-term royalty upside while securing immediate funding for commercial expansion and pipeline advancement. Combined with its licensing partnership in Europe, the company has already realized $210 million in upfront and milestone payments, with an additional $75 million anticipated in the near term.

Patients’ Significance

For patients, BEYONTTRA® and Attruby™ represent transformative therapies that not only reduce the burden of hospitalizations but also extend survival and improve quality of life. By stabilizing more than 90% of circulating TTR, the therapy addresses the root cause of ATTR-CM, offering hope to thousands of patients worldwide living with this progressive, life-threatening disease.

Policy Significance

As healthcare systems grapple with the rising burden of rare cardiovascular diseases, the integration of innovative therapies like acoramidis requires supportive reimbursement frameworks and value-based care models. Policymakers have an opportunity to ensure equitable patient access, while fostering innovation in the treatment of genetic diseases.

Transaction Highlights

  • Capital infusion: $300 million upfront payment from royalty monetization.
  • Royalty terms: 60% of European royalties on the first $500 million in annual net sales monetized; capped at 1.45x total payments

BridgeBio’s $300 million royalty monetization deal marks a milestone in strategic financing—unlocking immediate capital while protecting future growth potential. With strong clinical validation and global regulatory approvals, acoramidis stands poised for impactful market entry. Supported by seasoned healthcare investors, BridgeBio is well-positioned to advance its commercial and genetic medicine pipelines effectively.

Source: BridgeBio Press Release